Table 1 Baseline characteristics
Total (n=11,105) | Pitavastatin 1 mg/day (n = 5759) | Pitavastatin 4 mg/day (n = 5346) | |
|---|---|---|---|
Age, yr | 68.1±8.3 | 68.1±8.3 | 68.0±8.3 |
Age ≥65 yr, n (%) | 7512 (67.7) | 3913 (68.0) | 3599 (67.3) |
Male gender, n (%) | 9197 (82.8) | 4475 (82.5) | 4447 (83.2) |
Body mass index, kg/m2 | 24.7±3.4 | 24.6±3.4 | 24±3.3 |
Body mass index <25 kg/m2, n (%) | 6024 (57.8) | 3150 (58.3) | 2874 (57.4) |
Risk factor, n (%) | |||
Current smoking | 1812 (16.3) | 912 (15.8) | 900 (16.8) |
Hypertension | 8447 (76.1) | 4366 (75.8) | 4081 (76.3) |
Diabetes mellitus | 4445 (40.1) | 2296 (39.9) | 2159 (40.4) |
Chronic kidney disease | 3918 (35.8) | 2055 (36.2) | 1863 (35.4) |
LDL-C, mg/dl | |||
Baseline | 87.8±18.8 | 87.8±18.9 | 87.7±18.8 |
6 months | 81.1±21.6 | 89.0±21.1 | 72.7±18.8 |
Change (6 months − baseline) | −6.6±19.1 | 1.2±17.4 | −15.0±17.1 |
HDL-C (baseline), mg/dl | 50.6±12.4 | 50.7±12.7 | 50.5±12.2 |
Baseline HDL-C <40mg/dl, n (%) | 1977 (17.8) | 1045 (18.2) | 932 (17.4) |
TG (baseline), mg/dl | 124.0 (89.1, 174.0) | 124.0 (88.0, 173.0) | 125.0 (89.0, 177.0) |
Baseline TG ≥150mg/dl, n (%) | 3913 (35.3) | 2002 (34.8) | 1911 (35.8) |
hsCRP (6 months), mg/l | 0.480 (0.226, 1.070) | 0.520 (0.245, 1.170) | 0.439 (0.207, 0.960) |
hsCRP (6 months) ≥1.0 mg/l, n (%) | 2830 (26.7) | 1594 (29.0) | 1236 (24.1) |
Concomitant medications, n (%) | |||
Beta blockers | 4370 (42.1) | 2273 (42.2) | 2097 (42.1) |
Dual antiplatelet therapy | 4599 (44.3) | 2395 (44.4) | 2204 (44.2) |
ACE inhibitors/ARBs | 7006 (67.5) | 3636 (67.5) | 3370 (67.6) |
Previous history, n (%) | |||
Myocardial infarction | 5767 (51.9) | 2994 (52.0) | 2773 (51.9) |
Unstable angina | 2799 (25.2) | 1451 (25.2) | 1348 (25.2) |
PCI | 9304 (83.8) | 4800 (83.4) | 4504 (84.3) |
CABG | 1432 (12.9) | 741 (12.9) | 691 (12.9) |
Stroke | 851 (7.7) | 454 (7.9) | 397 (7.4) |
Atrial fibrillation | 684 (6.2) | 362 (6.3) | 322 (6.0) |
Malignant tumor | 592 (5.3) | 328 (5.7) | 264 (4.9) |
Chronic heart failure | 566 (5.1) | 309 (5.4) | 257 (4.8) |